R
10.45
0.40 (3.98%)
| Previous Close | 10.05 |
| Open | 9.90 |
| Volume | 391,451 |
| Avg. Volume (3M) | 238,506 |
| Market Cap | 5,181,991,936 |
| Price / Book | 2.43 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2026 |
| Diluted EPS (TTM) | -0.010 |
| Total Debt/Equity (MRQ) | 1.04% |
| Current Ratio (MRQ) | 41.92 |
| Operating Cash Flow (TTM) | -4.00 M |
| Levered Free Cash Flow (TTM) | -1.88 M |
| Return on Assets (TTM) | -28.11% |
| Return on Equity (TTM) | -43.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Regencell Bioscience Holdings L | - | - |
AIStockmoo Score
1.6
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 1.63 |
Select this tab to load the latest available analysis.
|
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 93.84% |
| % Held by Institutions | 0.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fox Run Management, L.L.C. | 30 Jun 2026 | 20,691 |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |